Biotechnology
Our team regularly advises clients developing biotech products in areas including biotechnology derived proteins (such as insulin), immunologicals (such as vaccines and allergens), blood or plasma derived products, and engineered tissues.
Our team benefits from having several members of the group who have completed degrees in subjects including molecular biology, biochemistry and genetics. This knowledge enables us to quickly grasp technical concepts and provide nuanced and tailored advice.
We closely follow new developments and emerging trends in the biotech market. For example, we have been following the emerging regulatory pathways for biosimilars and advising clients on appropriate strategies.
We have worked with many well-known companies on their biological products, including Pfizer, Novartis, Regeneron, Amgen and Roche.
Explore our sectors
Meet our lawyers
News & insights
Publications: 07 APRIL 2021
Compelling signals from a recovering M&A market
The question at the end of 2020 was whether the strong recovery in M&A activity could be sustained in 2021.
Read more
News: 12 FEBRUARY 2021
Allen & Overy advises Biogroup on two high-yield bond issues and a new senior facilities agreement
PARIS – Biogroup, the leading private medical laboratory services group in France and Belgium, has successfully completed through its two main subsidiaries the issuance of EUR800million in aggregate…
Read more
News: 01 FEBRUARY 2021
Allen & Overy continues to make gains with FTSE clients
In the Adviser Rankings 15th anniversary guide A&O is ranked 3rd for FTSE 100 with 23 clients, up from 17 in 2010, and A&O is one of only two magic circle firms to have grown their total stock market…
Read more
Publications: 15 DECEMBER 2020
Healthcare accent is on smaller deals
Transactions in the U.S. healthcare space rebounded in autumn, although with a greater proportion of smaller deals than in recent years.
Read moreDownload our sector brochure
